Immunicum - ilixadencel in MERECA Phase II - results soon ! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: loparn	10/4/2019 4:10:56 AM
	of 17

Immmunicum : A shorter-induced short-squeeze hopefully may have started in the IMMU.ST stock after the very positive complementary MERECA study data for tumor respons and for individual survival data that were presented Sept 25 (after initially "uncomplete" data Aug 29 causing shorters to attack) The stock price is still around half of the highest price in July before MERECA results. See the chart : tinyurl.com Look carefully at pages 12-15 in the pdf-file in the link below for the survival data including page 15 for a Kaplan-Meier-based forecast which clearly indicate that the ilixadencel treated group more likely will have ha better MOS when the data become mature within a year or so. immunicum.se This is only in mRCC but ilixadencel has a clear potential in all injectable solid tumors when combined with checkpoint inhibitors since the mechanism of action is independant of cancer indikation in solid tumors. Ilixadencel is a primer activating a broad tumor specific CD8+ T-cell respons.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next